Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening

Clinical Chemistry

Volumn 47, Issue 1, 2001, Pages 28-29

  Rifai, N ^a   Ridker, P M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LIPID;

CARDIOVASCULAR RISK; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MORTALITY; NOTE; RISK ASSESSMENT; SCREENING; SMOKING;

EID: 0035148488     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.1.28     Document Type: Note

References (15)

1. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
2. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project
3. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
4. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
5. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle aged men. Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
6. Infections, inflammation, and the risk of coronary heart disease
7. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
8. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
9. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
10. Clinical efficacy of an automated high sensitivity C-reactive protein assay
11. Long term effects of pravastatin on plasma concentration of C-reactive protein
12. Shattuck Lecture. Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities
13. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
14. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients
15. Atherosclerosis - An inflammatory disease